DeSelm, Lizbeth published the artcileIdentification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers, Computed Properties of 6850-57-3, the publication is Journal of Medicinal Chemistry (2021), 64(19), 14603-14619, database is CAplus and MEDLINE.
The discovery of a novel class of quinazoline carboxamides such as I [R1 = H, Me; R2 = Ph, 3-FC6H4, 4-MeOC6H4, etc.] as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway was reported. Through the screening of inhouse proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide 1 stood out, with sub-micromolar p70S6k biochem. activity, as the starting point for a structurally enabled p70S6K/Akt dual inhibitor program that led to the discovery of M2698, a dual p70S6k/Akt inhibitor. Compound M2698 [II] is kinase selective, possesses favorable phys., chem., and DMPK profiles, was orally available and well tolerated, and displayed tumor control in multiple in vivo studies of PAM pathway-driven tumors.
Journal of Medicinal Chemistry published new progress about 6850-57-3. 6850-57-3 belongs to ethers-buliding-blocks, auxiliary class Amine,Benzene,Ether, name is (2-Methoxyphenyl)methanamine, and the molecular formula is C8H11NO, Computed Properties of 6850-57-3.
Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem